Jackson, Dr Andrew



Clinical oncology


Gastrointestinal cancers, lung cancer, skin cancer

Training and education

  • Undergraduate training, University of Cambridge and St George’s Hospital Medical School, 1989 to 1995.
  • Membership of the Royal College of Physicians, 1998
  • Oncology training, pan-Thames training scheme, 1999 to 2006
  • Fellowship of the Royal College of Radiologists, 2003
  • MD, Royal Marsden Hospital and Institute of Cancer Research, 2003 to 2005.


Dr Jackson has worked for the Trust since October 2010.

He gained his CCST in clinical oncology in 2006 and took a post as a clinical lecturer and honorary consultant oncologist at The University of Manchester and Christie Hospital, specialising in upper gastrointestinal cancers, with additional academic interests in image guided radiotherapy (IGRT) and imaging.

In 2010, Dr Jackson he moved to UHS, with two days a week at North Hampshire Hospital.

He is continuing to pursue his research interest in upper gastrointestinal cancers.

Key achievements

  • Principal investigator, ROCOCO (Radiotherapy and Olaparib in Combination for Oesophageal Cancer) phase 1 dose escalation study. Awarded funding by CRUK New Agents Committee, January 2011.
  • Principal investigator, Christie Hospital, Manchester: PACER (Locally Advanced pancreatic cancer: Phase II study of Cetuximab and 3-D conformal Image Guided Radiotherapy). Three centre NCRN badged study.
  • Co-investigator, Christie Hospital, Manchester: ‘A real time visual feedback device for reducing patient movement during radiotherapy’, NIHR New and Emerging Applications of Technology (NEAT) award 2008
  • Principal investigator, Christie Hospital, Manchester: DCE-MRI in oesophageal cancer: a pilot study. University of Manchester Magnetic Resonance Imaging Facility.
  • Member of NCRI CTRad Workstream 3 (Phase III trials) (formerly clinical and translational radiotherapy research working group).

Awards and prizes

Rohan Williams Medal for FRCR, 2003


Dr Jackson's recent publications include

  • A Saleem, A. Jackson, S Mukherjee, N Stones, T Crosby, D Tait, P Price. Radiotherapy in the Management of Unresectable Locally Advanced Pancreatic Cancer: a Survey of the Current UK Practice of Clinical Oncologists. Clin Oncol (R Coll Radiol). 2010 May;22(4):257-60.
  • MT Guerrero Urbano, J Staffurth , A. Norman,, FM Buffa, A Jackson, EJ Adams, V Hansen, C Clark, L Miles, H McNair, CM Nutting, C Parker, V Khoo, R Eeles, R Huddart, A Horwich, DP Dearnaley. Intensity Modulated Radiotherapy (IMRT) allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: Results of a phase 1 dose escalation study. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):236-44.
  • ASN Jackson, P Jain, GR Watkins, , GA Whitfield, MM Green, J Valle, MB Taylor, C Dickinson, PM Price, A Saleem. Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. Clin Oncol (R Coll Radiol) 2010 Sep;22(7):570-7.
  • ASN Jackson, SA Reinsberg, SA Sohaib, EM Charles-Edwards, SG Jhavar, TJ Christmas, AC Thompson, MJ Bailey, CM Corbishley, C Fisher, MO Leach, DP Dearnaley. Dynamic Contrast Enhanced MRI for Prostate Cancer Localisation. Br J Radiol. 2009 Feb;82(974):148-56.
  • Raj Sripadam, Julie Stratford, Ann M. Henry, Andrew Jackson, Chris J. Moore, Pat Price. Rectal motion can reduce CTV coverage and increase rectal dose during prostate radiotherapy: a daily cone beam CT study. Radiother Oncol. 2009;90(3):312-317.